Long-term consequences of cardiac alteration in children with chronic renal failure and after renal transplantation are largely unknown. In chronic uremia, cardiomyopathy manifests itself as systolic dysfunction, concentric left ventricular hypertrophy (LVH) or left ventricular dilatation. The correction of uremic state by renal transplantation leads to normalization of left ventricular contrac...

T he growth and hypertrophy of left ventricular myocardium in response to pressure or volume overload or segmental loss of functional myocardium was once considered a purely beneficial, structural adaptation to reduce or normalize systolic and/or diastolic wall stress.' This concept has been challenged, however, by a growing body of evidence indicating that most forms of left ventricular hypert...

BACKGROUND Left ventricular hypertrophy (LVH) typically manifests during or after adolescence in sarcomere mutation carriers at risk for developing hypertrophic cardiomyopathy. Guidelines recommend serial imaging of mutation carriers without LVH (G+/LVH-) to monitor for phenotypic evolution, but the optimal strategy is undefined. Compared with echocardiography (echo), cardiac MRI (CMR) offers i...

AIMS Cardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS The study was performed in 124 patients with HCM. All patients underwent a full clinical...

Hypertrophy in Experimental Animals and Humans To the Editor: Barouch et al1 recently published a well-designed study demonstrating that left ventricular hypertrophy (LVH) occurs in mice that are either leptin-deficient (ob/ob) or leptin-resistant (db/db). They also found that systemic administration of leptin to the leptin-deficient animals attenuated LVH more than would be predicted by the le...

A recent study has demonstrated that adiponectin inhibited hypertrophic signaling in the myocardium of mice, implying that a decrease in the blood adiponectin level could cause cardiac muscle hypertrophy. We hypothesized that a relationship might exist between the serum adiponectin level and electrocardiographically diagnosed left ventricular hypertrophy (ECG-LVH), and we examined this hypothes...

BACKGROUND Many electrocardiographic (ECG) criteria for left ventricular hypertrophy (LVH) exist, but few studies have compared their relative prognostic value for predicting cardiovascular (CV) mortality. METHODS We analyzed the first ECG on 46950 consecutive veterans. We targeted male outpatients with a body mass index > 20 to avoid confounding by complicating catabolic illnesses and furthe...

Downregulation of the muscle-specific microRNA-1 (miR-1) mediates the induction of pathologic cardiac hypertrophy. Dysfunction of the gap junction protein connexin 43 (Cx43), an established miR-1 target, during cardiac hypertrophy leads to ventricular tachyarrhythmias (VT). However, it is still unknown whether miR-1 and Cx43 are interconnected in the pro-arrhythmic context of hypertrophy. Thus,...

Left ventricular hypertrophy (LVH), whether measured by electrocardiography, echocardiography, or at autopsy, is associated with increased risk of cardiovascular morbidity and mortality.1,2 Although LVH has been associated with several clinical characteristics such as age, sex, body mass index, and hypertension, the effects and their directionality have varied according to the criteria for LVH....

OBJECTIVE This study was designed to investigate whether plasma concentration of cardiotrophin-1 (CT-1), a cytokine that induces cardiomyocyte hypertrophy and stimulates cardiac fibroblasts, is related to hypertensive heart disease, as defined by the presence of echocardiographically assessed left ventricular hypertrophy (LVH). METHODS The study was performed in 31 normotensive subjects and 1...